U.S. Department of Health & Human Services      Search the NIH Website
          Virtual Tour
          Staff Directory
          En Español Site Menu Home
			
			Health Information
				Health Care Providers & Facilities
							Health Info Lines
							HealthCare.gov
							Science Education Resources
							NIH Clinical Research Trials and You
							Talking to Your DoctorMore »
					Search Health Topics
						Quick Links
						MedlinePlus Health Info
							NIH News in Health
							Wellness Toolkits
			
			Grants & Funding
				Grants Home Page
							Find Funding
							Due Dates
							How to Apply
							About Grants
							Policy & Compliance
							Grants News/Blog
							Contracts
							Loan RepaymentMore »
					Quick Links
						RePORT
							eRA Commons
							NIH Common Fund
			
			News & Events
				News Releases
							Digital Media Kits
							Media Resources
							Media Contacts
							Images and B-roll
							Events
							Social MediaMore »
					Quick Links
						NIH News in Health
							NIH Research Matters
							NIH Record
			
			Research & Training
				Medical Research Initiatives
							Science Highlights
							Science Education
							Research in NIH Labs & Clinics
							Training Opportunities
							Library Resources
							Research Resources
							Clinical Research Resources
							Safety, Regulation and GuidanceMore »
					Quick Links
						PubMed
							Stem Cell Information
							OppNet
							NIDB
							NIH Blueprint for Neuroscience Research
			
			Institutes at NIH
				List of Institutes and Centers
							NIH Office of the Director
							Directors of NIH Institutes and Centers
							NIH Institute and Center Contact InformationMore »
					Quick Links
						NCI
              	NEI
              	NHLBI
              	NHGRI
              	NIA
              	NIAAA
              	NIAID
              	NIAMS
              	NIBIB
              	NICHD
              	NIDCD
              	NIDCR
              	NIDDK
              	NIDA
              	NIEHS
              	NIGMS
              	NIMH
              	NIMHD
              	NINDS
              	NINR
              	NLM
              	CC
              	CIT
              	CSR
              	FIC
              	NCATS
              	NCCIH
			
			About NIH
				Who We Are
							What We Do
							Jobs at NIH
							Visitor Information
							Frequently Asked Questions
							Contact UsMore »
					Quick Links
						The NIH Director
							Take the Virtual Tour
							NIH...Turning Discovery Into Health®
							Impact of NIH Research
							Science, Health, and Public Trust
 You are here Home Research & Training Accelerating Medicines Partnership (AMP)
 Accelerating Medicines Partnership® (AMP®)
 Accelerating Medicines Partnership (AMP)
    
  Alzheimer’s Disease
Autoimmune and Immune-Mediated Diseases
Bespoke Gene Therapy Consortium
Common Metabolic Diseases
Heart Failure
Parkinson’s Disease
Rheumatoid Arthritis and Lupus
Schizophrenia
Type 2 Diabetes Autoimmune Diseases of Rheumatoid Arthritis and Lupus On this page About Rheumatoid Arthritis and Lupus
			Need for New Therapies
			AMP Approach
			Immunology Database and Analysis Portal
			Governance
			Budget
 Overview National Institutes of Health (NIH), 10 biopharmaceutical companies, and multiple non-profit organizations launched an unprecedented new public-private partnership in February 2014. Managed through the Foundation for the NIH (FNIH), the Accelerating Medicines Partnership® (AMP®) program brings high-level government, industry, and non-profit foundation partners together to identify and validate the most promising biological targets for therapeutics. The partners designed a bold milestone-driven research plan to tackle the challenge for the autoimmune diseases of rheumatoid arthritis and systemic lupus erythematosus (lupus), as well as for Alzheimer’s disease and type 2 diabetes. One of the features that makes this public-private partnership unique is that AMP data is publicly accessible to the broad biomedical community for further research. The Phase This fact sheet addresses the AMP research plan for rheumatoid arthritis and lupus. About Rheumatoid Arthritis and Lupus Rheumatoid arthritis (RA) and lupus are relatively common, severe disorders. About 1.5 million people or about 0.6 percent of the U.S. adult population have rheumatoid arthritis. Estimating how many people in the U.S. have lupus is difficult because symptoms vary widely and onset is often hard to pinpoint. Both conditions are autoimmune diseases that occur when the immune system mistakenly attacks parts of the body that it is designed to protect. They represent just two of a larger number of autoimmune disorders, including multiple sclerosis, Crohn’s disease, ulcerative colitis, type 1 diabetes, and psoriasis. These diseases share common flaws in immune function and regulation, leading to inflammation that destroys tissues. They can last a lifetime, cause severe disability, greatly affect quality of life, and are associated with increased risk of death. Need for New Therapies Treatments for these diseases typically have been aimed at decreasing inflammation and pain by slowing down tissue damage and reducing complications. Most people with RA have only a partial response to available drugs, and many only respond to drugs for a limited period of time. In the case of lupus, no effective targeted therapies exist for the most severe forms of the disease. Research is needed to better understand the underlying disease process and identify parts of the immune system that aren't functioning correctly. This insight will help reveal the most promising new biological targets for drug development and match existing drugs to patients with specific molecular profiles who are most likely to benefit. AMP Approach This project is analyzing, at the single cell level, tissue and blood samples from people with RA and lupus to pinpoint genes, proteins, biological pathways, and signaling networks. This type of analysis will allow insights into key aspects of diseases processes and allow comparisons between diseases. The project will explore differences between those RA patients who respond to therapies and those who do not, and will provide a better systems level understanding of disease mechanisms in both RA and lupus. This knowledge is essential for the development of targeted therapies and for the application of existing and future therapies to appropriate patient populations. Immunology Database and Analysis Portal The partnership is using several new or developing technologies to analyze information from single cells and groups of cells involved in autoimmunity; collecting tissue samples, including synovium (the tissue that lines joints) from people with RA and kidney from people with lupus for molecular analysis; developing computational tools to integrate different data types to characterize molecular pathways; and making the data available to the broad research community for further analysis through dbGaP (rheumatoid arthritis; lupus) and ImmPort (accession: SDY997, SDY998). The first datasets were released in 2018. Researchers mining the data can seek to identify treatment targets to develop medicines for diseases of interest. The data also has potential implications for precision medicine, as AMP RA/SLE researchers identify differences in the pathways active in the tissue of different patients. Governance The steering committee (SC) for RA and lupus is comprised of representatives from NIH, FNIH, and participating companies and non-profit organizations. The SC meets on a regular basis and is responsible for monitoring progress towards milestones. The SC operates under the direction of the overall AMP Executive Committee comprised of representatives from NIH, FNIH, participating companies, the Food and Drug Administration, and non-profit organizations. Budget: 6 years ($52.9 Million Total Project Funding) Disease area
			Total NIH funding ($M)
			**Total Industry funding ($M)**
			**Total non-profit funding ($M)**
			**T****otal project funding ($M)****Rheumatoid Arthritis and Lupus**
			24.9
			27.1
			1.2
			53.2 ***ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.***
 This page last reviewed on July 29, 2021
 Related LinksAMP research efforts for autoimmune diseasesAMP Rheumatoid Arthritis and Lupus: The Partners**Government**

NIH**Industry**

AbbVie
	Bristol-Myers Squibb
	GlaxoSmithKline
	Janssen
	Merck
	Pfizer
	Sanofi
	Takeda**Non-Profit Organizations**

Arthritis Foundation
	Foundation for the NIH
	Lupus Foundation of America
	Lupus Research Alliance
	Rheumatology Research Foundation
 Connect with Us Contact Us
      X
      Facebook
      Instagram
      YouTube
      Flickr
      More Social Media from NIH
 Footer
    NIH Home
      Virtual Tour
      En Español
      Visitor Information
      Frequently Asked Questions
      Privacy Policy
      Disclaimers
      Accessibility
      NIH Website ArchivesNondiscrimination Notice
      Freedom of Information Act
      No Fear Act
      HHS Vulnerability Disclosure
      Office of Inspector General
      USA.govNIH...Turning Discovery Into Health®
    National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892
    U.S. Department of Health and Human Services
 Back to Top